Gallbladder disease, cholecystectomy, and pancreatic cancer risk in the International Pancreatic Cancer Case-Control Consortium (PanC4).


Journal

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837

Informations de publication

Date de publication:
09 2020
Historique:
entrez: 3 8 2020
pubmed: 3 8 2020
medline: 31 8 2021
Statut: ppublish

Résumé

The association among gallbladder disease, cholecystectomy, and pancreatic cancer is unclear. Moreover, time interval between gallbladder disease or cholecystectomy and pancreatic cancer diagnosis is not considered in most previous studies. To quantify the association among gallbladder disease, cholecystectomy, and pancreatic cancer, considering time since first diagnosis of gallbladder disease or cholecystectomy. We used data from nine case-control studies within the Pancreatic Cancer Case-Control Consortium, including 5760 cases of adenocarcinoma of the exocrine pancreas and 8437 controls. We estimated pooled odds ratios and the corresponding 95% confidence intervals by estimating study-specific odds ratios through multivariable unconditional logistic regression models, and then pooling the obtained estimates using fixed-effects models. Compared with patients with no history of gallbladder disease, the pooled odds ratio of pancreatic cancer was 1.69 (95% confidence interval, 1.51-1.88) for patients reporting a history of gallbladder disease. The odds ratio was 4.90 (95% confidence interval, 3.45-6.97) for gallbladder disease diagnosed <2 years before pancreatic cancer diagnosis and 1.11 (95% confidence interval, 0.96-1.29) when ≥2 years elapsed. The pooled odds ratio was 1.64 (95% confidence interval, 1.43-1.89) for patients who underwent cholecystectomy, as compared to those without cholecystectomy. The odds ratio was 7.00 (95% confidence interval, 4.13-11.86) for a surgery <2 years before pancreatic cancer diagnosis and 1.28 (95% confidence interval, 1.08-1.53) for a surgery ≥2 years before. There appears to be no long-term effect of gallbladder disease on pancreatic cancer risk, and at most a modest one for cholecystectomy. The strong short-term association can be explained by diagnostic bias and reverse causation.

Sections du résumé

BACKGROUND
The association among gallbladder disease, cholecystectomy, and pancreatic cancer is unclear. Moreover, time interval between gallbladder disease or cholecystectomy and pancreatic cancer diagnosis is not considered in most previous studies.
AIM
To quantify the association among gallbladder disease, cholecystectomy, and pancreatic cancer, considering time since first diagnosis of gallbladder disease or cholecystectomy.
METHODS
We used data from nine case-control studies within the Pancreatic Cancer Case-Control Consortium, including 5760 cases of adenocarcinoma of the exocrine pancreas and 8437 controls. We estimated pooled odds ratios and the corresponding 95% confidence intervals by estimating study-specific odds ratios through multivariable unconditional logistic regression models, and then pooling the obtained estimates using fixed-effects models.
RESULTS
Compared with patients with no history of gallbladder disease, the pooled odds ratio of pancreatic cancer was 1.69 (95% confidence interval, 1.51-1.88) for patients reporting a history of gallbladder disease. The odds ratio was 4.90 (95% confidence interval, 3.45-6.97) for gallbladder disease diagnosed <2 years before pancreatic cancer diagnosis and 1.11 (95% confidence interval, 0.96-1.29) when ≥2 years elapsed. The pooled odds ratio was 1.64 (95% confidence interval, 1.43-1.89) for patients who underwent cholecystectomy, as compared to those without cholecystectomy. The odds ratio was 7.00 (95% confidence interval, 4.13-11.86) for a surgery <2 years before pancreatic cancer diagnosis and 1.28 (95% confidence interval, 1.08-1.53) for a surgery ≥2 years before.
CONCLUSIONS
There appears to be no long-term effect of gallbladder disease on pancreatic cancer risk, and at most a modest one for cholecystectomy. The strong short-term association can be explained by diagnostic bias and reverse causation.

Identifiants

pubmed: 32740166
doi: 10.1097/CEJ.0000000000000572
pii: 00008469-202009000-00005
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

408-415

Références

Bosetti C, Tavani A, Negri E, Trichopoulos D, La Vecchia C. Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol. 2001; 54:902–906
Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012; 23:1880–1888
Bosetti C, Rosato V, Li D, Silverman D, Petersen GM, Bracci PM, et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the international pancreatic cancer case-control consortium. Ann Oncol. 2014; 25:2065–2072
Brenner DR, Wozniak MB, Feyt C, Holcatova I, Janout V, Foretova L, et al. Physical activity and risk of pancreatic cancer in a central European multicenter case-control study. Cancer Causes Control. 2014; 25:669–681
Breslow NE, Day NE. IARC Sci Publ No. 32. Statistical methods in cancer research. Vol. I. The analysis of case-control studies. 1980, Lyon, France: IARC
Chow WH, Johansen C, Gridley G, Mellemkjaer L, Olsen JH, Fraumeni JF Jr. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer. 1999; 79:640–644
Cuzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int J Cancer. 1989; 43:415–421
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177–188
Fan Y, Hu J, Feng B, Wang W, Yao G, Zhai J, Li X. Increased risk of pancreatic cancer related to gallstones and cholecystectomy: a systematic review and meta-analysis. Pancreas. 2016; 45:503–509
Fernandez E, La Vecchia C, Decarli A. Attributable risks for pancreatic cancer in Northern Italy. Cancer Epidemiol Biomarkers Prev. 1996; 5:23–27
Gomez-Rubio P, Zock JP, Rava M, Marquez M, Sharp L, Hidalgo M, et al.; PanGenEU Study Investigators. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut. 2017; 66:314–322
Gong Y, Li S, Tang Y, Mai C, Ba M, Jiang P, Tang H. Cholelithiasis and risk of pancreatic cancer: systematic review and meta-analysis of 21 observational studies. Cancer Causes Control. 2014; 25:1543–1551
Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987; 9:1–30
Gullo L, Pezzilli R, Morselli-Labate AM; Italian Pancreatic Cancer Study Group. Risk of pancreatic cancer associated with cholelithiasis, cholecystectomy, or gastrectomy. Dig Dis Sci. 1996; 41:1065–1068
Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002; 21:2409–2419
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–560
Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Karakatsani A, Trichopoulos D. Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control. 1993; 4:375–382
Ko AH, Wang F, Holly EA. Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control. 2007; 18:809–819
Lai HC, Tsai IJ, Chen PC, Muo CH, Chou JW, Peng CY, et al. Gallstones, a cholecystectomy, chronic pancreatitis, and the risk of subsequent pancreatic cancer in diabetic patients: a population-based cohort study. J Gastroenterol. 2013; 48:721–727
Lin G, Zeng Z, Wang X, Wu Z, Wang J, Wang C, et al. Cholecystectomy and risk of pancreatic cancer: a meta-analysis of observational studies. Cancer Causes Control. 2012; 23:59–67
Lipworth L, Zucchetto A, Bosetti C, Franceschi S, Talamini R, Serraino D, et al. Diabetes mellitus, other medical conditions and pancreatic cancer: a case-control study. Diabetes Metab Res Rev. 2011; 27:255–261
Lucenteforte E, La Vecchia C, Silverman D, Petersen GM, Bracci PM, Ji BT, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the international pancreatic cancer case-control consortium (PanC4). Ann Oncol. 2012; 23:374–382
Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis. 2010; 28:645–656
Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, Ghadirian P, Baghurst PA, Zatonski WA, et al. Past medical history and pancreatic cancer risk: results from a multicenter case-control study. Ann Epidemiol. 2010; 20:92–98
McWilliams RR, Bamlet WR, de Andrade M, Rider DN, Cunningham JM, Petersen GM. Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L. Cancer Epidemiol Biomarkers Prev. 2009; 18:1295–1302
Nogueira L, Freedman ND, Engels EA, Warren JL, Castro F, Koshiol J. Gallstones, cholecystectomy, and risk of digestive system cancers. Am J Epidemiol. 2014; 179:731–739
Olson SH. Selected medical conditions and risk of pancreatic cancer. Mol Carcinog. 2012; 51:75–97
Olson SH, Orlow I, Simon J, Tommasi D, Roy P, Bayuga S, et al. Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. Cancer Detect Prev. 2007; 31:345–351
Rosato V, Polesel J, Bosetti C, Serraino D, Negri E, La Vecchia C. Population attributable risk for pancreatic cancer in Northern Italy. PANCREAS. 2015; 44:216–220
Santibañez M, Vioque J, Alguacil J, de la Hera MG, Moreno-Osset E, Carrato A, et al. Occupational exposures and risk of pancreatic cancer. Eur J Epidemiol. 2010; 25:721–730
Schwarzer G. Meta: General Package for Meta-Analysis. R package version 4.4-0. 2016. https://CRAN.R-project.org/package=meta. [Accessed 3 July 2019]
Shabanzadeh DM, Sørensen LT, Jørgensen T. Association between screen-detected gallstone disease and cancer in a cohort study. Gastroenterology. 2017; 152:1965–1974.e1
Smith JP, Solomon TE, Bagheri S, Kramer S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci. 1990; 35:1377–1384
Zhang J, Prizment AE, Dhakal IB, Anderson KE. Cholecystectomy, gallstones, tonsillectomy, and pancreatic cancer risk: a population-based case-control study in Minnesota. Br J Cancer. 2014; 110:2348–2353

Auteurs

Valentina Rosato (V)

Unit of Medical Statistics and Biometry, National Cancer Institute, IRCCS Foundation.

Eva Negri (E)

Department of Biomedical and Clinical Sciences, University of Milan.

Cristina Bosetti (C)

Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Núria Malats (N)

Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain.

Paulina Gomez-Rubio (P)

Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain.

PanGenEU Consortium (P)

Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain.

Patrick Maisonneuve (P)

Division of Epidemiology and Biostatistics, IEO European Institute of Oncology IRCCS, Milan, Italy.

Anthony B Miller (AB)

Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

H Bas Bueno-de-Mesquita (HB)

National Institute for Public Health and the Environment (RIVM), Bilthoven.
Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Peter A Baghurst (PA)

Public Health, Women's and Children's Hospital, Adelaide, South Australia, Australia.

Witold Zatonski (W)

Health Promotion Foundation, Nadarzyn.
Cancer Center and Institute of Oncology, Warsaw, Poland.

Gloria M Petersen (GM)

Department of Health Sciences Research, Medicine and Medical Genetics, Mayo Clinic, Rochester, New York, USA.

Ghislaine Scelo (G)

International Agency for Research on Cancer (IARC), Lyon, France.

Ivana Holcatova (I)

Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Eleonora Fabianova (E)

Regional Authority of Public Health, Banská Bystrica, Slovak Republic.
Faculty of Health, Catholic University, Ružomberok, Slovak Republic.

Diego Serraino (D)

Cancer Epidemiology Unit, National Cancer Institute Centro di Riferimento Oncologico, IRCCS, Aviano, Italy.

Sara H Olson (SH)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Jesús Vioque (J)

Institute for Health and Biomedical Research ISABIAL-UMH, Alicante.
CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.

Pagona Lagiou (P)

Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Athens, Greece.
Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.

Eric J Duell (EJ)

Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Paolo Boffetta (P)

The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA.

Carlo La Vecchia (C)

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH